-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date'
-
-
-
-
-
-
-
Savara (SVRA) PT Raised to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Savara secures $75 million funding from RTW for drug launch
-
-
-
-
-
-
-
Savara (SVRA) PT Raised to $6 at Oppenheimer
-
-
-
-
-
-
-
Savara (SVRA) Receives Refusal to File (RTF) Letter From FDA for BLA for MOLBREEVI
-
-
-
-
-
-
-
Savara (SVRA) Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (HTGC)
-
-
-
-
-
-
-
Savara (SVRA) Reports In-Line Q3 EPS
-
416,803 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

